FDA Discusses Biosimilars

The government says regulatory requirements for generic biological therapies will have to be tailored to the treatment in question.

By | August 8, 2011

Senior officials at the US Food and Drug Administration laid out their guiding philosophy on regulating the production of generic versions of biological drugs such as antibodies, insulin or other proteins last Wednesday (August 3) in the New England Journal of Medicine.

Biologics generally have a more complicated production process than small molecule drugs, impeding the ability of generic manufacturers to prove they are producing an identical drug. Drug companies, therefore, have been eagerly awaiting guidance from the FDA as to what constitutes a sufficient level of "biosimilarity" to allow a generic version of a drug to be approved.

In the article, Janet Woodcock, the director of the FDA’s Center for Drug Evaluation and Research (CDER), and others said that "given the complex nature of biologics, it's unlikely that a 'one size fits all' systematic assessment of biosimilarity can be developed."   While the article further stated that unnecessary "and therefore unethical" clinical and preclinical testing of biosimilars should be avoided, it also suggested that more data will be necessary to determine a generic’s similarity to the original than what is required for small molecule generics, according to Reuters.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Comments

Avatar of: prasanta

Anonymous

August 8, 2011

When the world is trying to rationalize on the availability of life-saving biologics at affordable prices , regulatory  complications are expected to be ironed out .

Avatar of:

Posts: 0

August 8, 2011

When the world is trying to rationalize on the availability of life-saving biologics at affordable prices , regulatory  complications are expected to be ironed out .

Avatar of:

Posts: 0

August 8, 2011

When the world is trying to rationalize on the availability of life-saving biologics at affordable prices , regulatory  complications are expected to be ironed out .

Popular Now

  1. That Other CRISPR Patent Dispute
    Daily News That Other CRISPR Patent Dispute

    The Broad Institute and Rockefeller University disagree over which scientists should be named as inventors on certain patents involving the gene-editing technology.

  2. How Gaining and Losing Weight Affects the Body
    Daily News How Gaining and Losing Weight Affects the Body

    Millions of measurements from 23 people who consumed extra calories every day for a month reveal changes in proteins, metabolites, and gut microbiota that accompany shifts in body mass.

  3. Neurons Use Virus-Like Proteins to Transmit Information
  4. DOE-Sponsored Oak Ridge National Laboratory to Cut 100 More Jobs
AAAS